Preventing Cervical Cancer and Other HPV-Related Diseases

HPV Vaccine Providers

HPV (Human Papilloma Virus) Infection:
What do we know?

HPV is found in 99.7% of invasive cervical cancers
HPV is a transmitted by intimate skin-to-skin contact
Cancer/cervical intraepithelial neoplasia contains 1 of 18 oncogenic viral HPV types
Approximately 90% of HPV infections resolve within two years
Persistent infection with a high-risk type is associated with disease progression and cancer
All patients with High-Risk HPV need treatment and follow-up

United States HPV Female Infection Statistics

By 50 years of age, at least 80% of women will have acquired genital HPV infection.
In sexually active individuals 15–24 years of age, ~9.2 million are currently infected.2
An estimated 74% of new HPV infections occur in this age group (ages15-24).
In studies of women <25 years of age, prevalence rates of HPV infection ranged from 28% to 46%.
Estimated Annual Burden of HPV-Related Diagnoses in the United States: 3.6 billion dollars

GARDASIL: The First Cervical Cancer Vaccine in the United States

GARDASIL is a prophylactic quadrivalent HPV L1 virus-like particle (VLP) vaccine against HPV Types 6, 11, 16, and 18. These HPV types cause 90% of all genital warts and 70% of all cervical cancer in the world.

ACIP (Advisory Committee on Immunization Practices, Center for Disease Control) Recommendations:

Routine vaccination with 3 doses of quadrivalent HPV vaccine for females 11–12 years of age
Can be started in females as young as 9 years of age
Catch-up vaccination for females 13–26 years of age not previously vaccinated or who have not completed the full vaccine series
Ideally, vaccine should be administered before potential exposure to HPV through sexual contact.
However, females who might have been exposed to HPV should be vaccinated.
Each dose of quadrivalent HPV vaccine is 0.5 mL, administered intramuscularly.
Quadrivalent HPV vaccine is administered in a 3-dose schedule.
The second and third doses should be administered 2 and 6 months after the first dose.
Quadrivalent HPV vaccine can be administered at the same visit at which other age-appropriate vaccines are provided, such as Tdap and quadrivalent meningococcal conjugate (MCV4).*
Current recommendations for cervical cancer screening have not changed for females who receive quadrivalent HPV vaccine.
Females who have an equivocal or abnormal Pap test, a positive Hybrid Capture II high-risk test, or genital warts can receive the quadrivalent HPV vaccine.
Recipients should be advised that the vaccine will not have any therapeutic or treatment effect on existing HPV infection, cervical lesions, or genital warts. Vaccination would only provide protection against infection with vaccine HPV types not already acquired.
Quadrivalent HPV vaccine is contraindicated in people with a history of immediate hypersensitivity to yeast or to any vaccine component.
Quadrivalent HPV vaccine is not recommended for use in pregnancy.
Individuals should report any exposure to the vaccine during pregnancy to the vaccine pregnancy registry.
Quadrivalent HPV vaccine can be administered to females with minor acute illnesses.
Vaccination of people with moderate or severe acute illnesses should be deferred until after the patient improves.
Syncope can occur after vaccination, most commonly among adolescents and young adults. (RARE)

Overall Conclusions for GARDASIL®

The Most Effective Time to Vaccinate Is Before Exposure1
The vaccine is highly effective in preventing cervical cancer and all pre-cancerous lesions caused by HPV 6, 11, 16, and 18 in 16- to 26-year-old women naïve to the these relevant HPV types.
Duration of efficacy is demonstrated greater than 5 years and additional data is forthcoming regarding how long the immunity will last.
The vaccination has a favorable tolerability profile with redness at injection site and low grade fever being the only noted side effects different than placebo.

HPV Vaccine Providers

PARTNERS